The role of the protein-binding on the mode of drug action as well the interactions with other drugs

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 33, Issue 4, 2008, Pages 225-230

  Tesseromatis, Christine ^a   Alevizou, Anastasia ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Drug binding; Drugs interactions; Serum; Tissues proteins

Indexed keywords

ALBUMIN; AMPICILLIN; BETA LACTAM; CEPHALOSPORIN; CHLORPROMAZINE; FATTY ACID; IBUPROFEN; LIDOCAINE; LIGANDIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLASMA PROTEIN; PROPANOL; QUINOLONE DERIVATIVE; WARFARIN;

ACIDITY; ALBUMIN BLOOD LEVEL; ARTICLE; BINDING AFFINITY; BINDING SITE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG PROTEIN BINDING; DRUG TRANSFORMATION; DRUG TRANSPORT; FATTY ACID BLOOD LEVEL; HYDROPHOBICITY; KIDNEY FAILURE; LIGAND BINDING; MENTAL STRESS; NONHUMAN; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; STRESS;

EID: 59949085146     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190876     Document Type: Article

References (57)

1. Benkestock K., Edlund P.O., Roeraade J. (2005): Electros-pray ionization mass spectrometry as a tool for determination of drug binding sites to human serum albumin by noncovalent interaction. Rapid Commun. Mass Spectrom., 19, 1637-1643.
2. Sudlow G., Birkett D.J., Wade D.N. (1975): The characterization of two specific drug binding sites on human serum albumin. Mol. Pharmacol., 11, 824-832.
3. Wanwimolruk S., Birkett D.J., Brooks P.M. (1983): Structural requirements for drug binding to site II on human serum albumin. Mol. Pharmacol., 24, 458-463.
4. Frostell-Karlsson A., Remaeus A., Roos H., Andersson K., Borg P., Hämäläinen M., Karlsson R. (2000): Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels. J. Med. Chem., 43, 1986-1992.
5. Olsen H., Andersen A., Nordbø A., Kongsgaard U.E., Børmer O.P. (2004): Pharmaceutical-grade albumin: impaired drug-binding capacity in vitro. BMC Clin, Pharmacol., 4: 4.
6. Kragh-Hansen U. (1988): Evidence for a large and flexible region of human serum albumin possessing high affinity binding sites for salicylate, warfarin, and other ligands. Mol. Pharmacol., 34, 160-171.
7. Prijovich Z.M., Leu Y.L., Roffler S.R. (2007): Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin. Cancer Chemother Pharmacol., 60, 7-17.
8. Hu O.Y., Chu K.M., Liu H.S., Chiao S.F., Ho W., Ho S.T. (1993): Reinduction of the hypnotic effects of thiopental with NSAIDs by decreasing thiopental plasma protein binding in humans. Acta Anaesthesiol. Scand., 37, 258-261.
9. Birkett D.J., Myers S.P., Sudlow G. (1977): Effects of fatty acids on two specific drug binding sites on human serum albumin. Mol. Pharmacol., 13, 987-992.
10. Vorum H., Honore B. (1996): Influence of fatty acids on the binding of warfarin and phenprocoumon to human serum albumin with relation to anticoagulant therapy. J. Pharm. Pharmacol., 48, 870-875
11. Ivarsen R., Brodersen R. (1989): Displacement of bilirubin from adult and newborn serum albumin by a drug and fatty acid. Dev. Pharmacol. Ther., 12, 19-29.
12. Sansom L.N., Evans A.M. (1995): What is the true clinical significance of plasma protein binding displacement interactions? Drug Saf, 12, 227-233.
13. Simard J.R., Zunszain P.A., Hamilton J.A., Curry S. (2006): Location of high and low affinity fatty acid binding sites on human serum albumin revealed by NMR drug-competition analysis. J. Mol. Biol., 361, 336-351.
14. Wosilait W.D., Ryan M.P. (1979): The effects of oleic acid, tolbutamide, and oxyphenbutazone on the binding of warfarin by human serum albumin. Res. Commun. Chem. Pathol. Pharmacol., 25, 577-584.
15. Huang B.X., Dass C., Kim H.Y. (2005): Probing conformational changes of human serum albumin due to unsaturated fatty acid binding by chemical cross-linking and mass spectrometry. Biochem. J., 387(Pt 3), 695-702.
16. Urien S., Albengres E., Zini R., Tillement J.P. (1982): Evidence for binding of certain acidic drugs to alpha 1-acid glycoprotein. Biochem. Pharmacol., 31, 3687-3689.
17. Holladay J.W., Dewey M.J., Michniak B.B., Wiltshire H., Halberg D.L., Weigl P., Liang Z., Halifax K., Lindup W.E., Back D.J. (2001): Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir. Drug Metab. Dispos., 29, 299-303.
18. Zhou H.H., Adedoyin A., Wilkinson G.R. (1990): Differences in plasma binding of drugs between Caucasians and Chinese subjects. Clin. Pharmacol. Ther., 48, 10-17.
19. Belpaire F.M., Bogaert M.G., Mussche M.M. (1977): Influence of acute renal failure on the protein binding of drugs in animals and in man. Eur. J. Clin. Pharmacol., 11, 27-32.
20. Henderson S.J., Lindup W.E. (1990): Interaction of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, an inhibitor of plasma protein binding in uraemia, with human albumin, Biochem. Pharmacol., 40, 2543-2548.
21. Viani A., Rizzo G., Carrai M., Pacifici G.M. (1992): The effect of ageing on plasma albumin and plasma protein binding of diazepam, salicylic acid and digitoxin in healthy subjects and patients with renal impairment. Br. J. Clin. Pharmacol., 33, 299-304.
22. 13C nuclear magnetic resonance study, J. Clin. Invest., 87, 1431-1441.
23. Vorum H., Jorgensen H.R., Brodersen R. (1993): Variation in the binding affinity of warfarin and phenprocoumon to human serum albumin in relation to surgery. Eur. J. Clin. Pharmacol., 44. 157-162.
24. Vorum H., Fisker K,, Honore B. (1997): Palmitate and stearate binding to human serum albumin. Determination of relative binding constants. J. Pept. Res., 49, 347-354.
25. Tsutsumi Y., Maruyama T., Takadate A., Goto M., Matsunaga H., Otagiri M (1999): Interaction between two dicarboxylate endogenous substances, bilirubin and an uremic toxin, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, on human serum albumin. Pharm. Res., 16, 916-923.
26. Sakai T., Yamasaki K., Sako T., Kragh-Hansen U., Suenaga A., Otagiri M. (2001): Interaction mechanism between indoxyl sulfate, a typical uremic toxin bound to site II, and ligands bound to site I of human serum albumin, Pharm. Res., 18, 520-524.
27. Soltys B.J., Hsia J.C. (1978): Steroid modulation of human serum albumin binding properties. A spin label study. J. Biol. Chem., 253, 4266-4269.
28. Bhattacharya A.A., Curry S., Franks N.P. (2000): Binding of the general anesthetics propofol and halothane to human serum albumin. High resolution crystal structures. J. Biol. Chem., 275, 38731-38738.
29. Petitpas I., Grune T., Bhattacharya A.A., Curry S. (2001): Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids. J. Mol. Biol., 314, 955-960.
30. Petersen C.E., Ha C.E., Curry S., Bhagavan N.V. (2002): Probing the structure of the warfarin-binding site on human serum albumin using site-directed mutagenesis. Proteins, 47, 116-125.
31. Tsopanakis C., Tesserommatis C. (1991): Cold swimming stress: effects on serum lipids, lipoproteins and LCAT activity in male and female rats. Pharmacol. Biochem. Behav., 38, 813-816.
32. Tesserommatis C., Tsopanakis C., Varonos D. (1988): Changes in serum lipids with the presence of various factors. Beitr. Infusionsther., 23, 195-197.
33. Saranteas T., Tesseromatis C., Potamianou A., Mourouzis C., Varonos D. (2002): Stress-induced lidocaine modification in serum and tissues. Eur. J. Drug Metabol. Pharmacokinet., 27, 229-232.
34. Tesseromatis C., Trichilis A., Tsivos E., Messari J., Triantaphyllidis H., Varonos D.D. (2001): Does stress influence ampicillin concentration in serum and tissues? Eur. J. Drug Metab01. Pharmacokinet., 26, 167-171.
35. Tesserommatis C., Tsopanakis C., Symeonoglou G., Loukissa M., Kouvarou E., Varonos D.D. (1996): How harmless is FFA enhancement? Eur. J. Drug Metabol. Pharmacokinet., 21, 213.
36. Trichilis A., Saranteas T., Potamianou A., Mourouzis C., Tesseromatis C. (2003): Quinolone levels in serum and maxillofacial tissues under ibuprofen co-administration following surgical trauma. J. Musculoskelet. Neuronal Interact., 3, 170-175.
37. Trichilis A., Tesserommatis C., Varonos D. (2000): Changes in serum levels of quinolones in rats under the influence of experimental trauma. Eur. J. Drug Metabol. Pharmacokinet., 25, 73-78.
38. Saranteas T., Zotos N., Lolis E., Stranomiti J., Mourouzis C., Chantzi C., Tesseromatis C. (2005): Mechanisms of ketamine action on lipid metabolism in rats. Eur. J. Anaesthesiol., 22, 222-226.
39. Ghuman J., Zunszain P.A., Petitpas I., Bhattacharya A.A., Otagiri M., Curry S. (2005): Structural basis of the drug-binding specificity of human serum albumin. J. Mol. Biol. 353, 38-52.
40. Tigka E., Daskala I., Rallis G., Anagnostopoulou S., Tesseromatis C. (2005): Adjuvant arthritis-induced changes on ampicillin binding in serum and tissues under the influence of non-steroidal anti-inflammatory drugs in rats. Eur. J. Drug Metabol. Pharmacokinet., 30, 235-241.
41. Saranteas T., Zotos N., Chantzi C., Mourouzis C., Rallis G., Anagnostopoulou S., Tesseromatis C. (2005): Ketamine-induced changes in metabolic and endocrine parameters of normal and 2-kidney 1-clip rats. Eur. J. Anaesthesiol., 22, 875-878.
42. Tillement J.P., Lhoste F., Giudicelli J.F. (1979): Diseases and drug protein binding. Clin. Pharmacokinet., 3, 144-154.
43. Perucca E. (1980): Plasma protein binding of phenytoin in health and disease: relevance to therapeutic drug monitoring. Ther. Drug Monit., 2, 331-344.
44. Tsivou E., Melakopoulos I., Kotsiou A., Anagnostopoulou S., Tesseromatis C. (2005): Alterations in cefalosporin levels in the serum and mandible of hyperlipaedemic rats after co-administration of ibuprofen. Eur. J. Drug Metabol. Pharmacokinet., 30, 171-174.
45. Melakopoulos I., Tesseromatis C., Saranteas T., Karabinos I. (1997): Changes of serum and tissue amoxicillin levels following chlorpromazine administration in rats. Anaerobe, 3, 103-105.
46. Saranteas T., Mourouzis C., Dannis C., Alexopoulos C., Lolis E., Tesseromatis C. (2004): Effect of various stress models on lidocaine pharmacokinetic properties in the mandible after masseter injection. J. Oral Maxillofac. Surg., 62, 858-862.
47. 4 induced liver damage. Eur. J. Drug Metabol. Pharmacokinet., 31, 97-101.
48. Tesseromatis C., Kotsiou A., Tsagataki M., Tigka E., Vovou J., Alevizou A., Perisanidis C., Saranteas T., Karakitsos D., Karabinis A., Kostopanagiotou G. (2007): In vitro binding of lidocaine to liver tissue under the influence of propranolol: another mechanism of interaction? Eur J Drug Metabol. Pharmacokinet., 32, 213-217.
49. Fichtl B., Gerdsmeier W. (1981): Increased plasma protein binding of propranolol in rabbits with acute renal failure. Life Sciences, 28, 31-35.
50. Fichtl B. (1990): The influence of renal failure on-drug binding in plasma and tissues. Nieren-und Hochdruckkrankheiten, 19, 447-449.
51. Bree F., Houin G., Barre J., Moretti J.L., Wirquin V., Tillement J.P., (1986): Pharmacokinetics of intravenously administered 125I-labelled human alpha 1-acid glycoprotein. Clin. Pharmacokinet., 11, 336-342.
52. Fichtl B., Nieciecki A., Walter K. (1991): Tissue binding versus plasma binding of drugs: General Principles and Pharmacokinetic Consequences. Adv. Drug Res., 20, 117-166.
53. Habig W.H., Pabst M.J., Fleischner G., Gatmaitan Z., Arias I.M., Jakoby W.B. (1974): The identity of glutathione S-transferase B with ligandin, a major binding protein of liver. Proc. Natl. Acad. Sci. USA, 71, 3879-3882.
54. Saranteas T., Mourouzis C., Koumoura F., Tesseromatis C. (2003): Effects of propranolol or paracetamol on lidocaine concentrations in serum and tissues. J. Oral Maxillofac. Surg., 61, 604-607.
55. Tesseromatis C. Saranteas T., Chatzijanni E., Anagnostopoulou S., Cotsiou A., Chantzi C. (2003): Modifications of clonidine binding to rabbit liver protein under the influence of non-steroid-anti-inflammatory drugs in vitro. Eur. J. Drug Metabol. Pharmacokinet., 28, 245-247.
56. Fichtl B., Kurz H. (1978): Binding of drugs to human muscle. Eur. J. Clin. Pharmacol., 14, 335-340.
57. Tesseromatis C., Fichtl B., Kurz H. (1987): Binding of non-steroid anti-inflammatory drugs and warfarin to liver tissue of rabbits in vitro. Eur. J. Drug Metabol. Pharmacokinet., 12, 161-167.